These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 35973732)

  • 21. Long-term renal follow-up of children treated with cisplatin, carboplatin, or ifosfamide: a pilot study.
    McMahon KR; Harel-Sterling M; Pizzi M; Huynh L; Hessey E; Zappitelli M
    Pediatr Nephrol; 2018 Dec; 33(12):2311-2320. PubMed ID: 30218190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cognitive Function and Kidney Disease: Baseline Data From the Systolic Blood Pressure Intervention Trial (SPRINT).
    Weiner DE; Gaussoin SA; Nord J; Auchus AP; Chelune GJ; Chonchol M; Coker L; Haley WE; Killeen AA; Kimmel PL; Lerner AJ; Oparil S; Saklayen MG; Slinin YM; Wright CB; Williamson JD; Kurella Tamura M;
    Am J Kidney Dis; 2017 Sep; 70(3):357-367. PubMed ID: 28606731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial.
    Heerspink HJL; Oshima M; Zhang H; Li J; Agarwal R; Capuano G; Charytan DM; Craig J; de Zeeuw D; Di Tanna GL; Levin A; Neal B; Perkovic V; Wheeler DC; Yavin Y; Jardine MJ
    Am J Kidney Dis; 2022 Feb; 79(2):244-256.e1. PubMed ID: 34029680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
    JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of blood pressure-lowering treatment by the levels of baseline Framingham risk score: A post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT).
    Zhang L; Sun X; Liao L; Zhang S; Zhou H; Zhong X; Zhuang X; Liao X
    J Clin Hypertens (Greenwich); 2019 Dec; 21(12):1813-1820. PubMed ID: 31670874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blood Pressure Variability Predicts Adverse Events and Cardiovascular Outcomes in Chronic Kidney Disease: A Post-Hoc Analysis of the SPRINT Trial.
    Mezue K; Goyal A; Pressman GS; Horrow JC; Rangaswami J
    Am J Hypertens; 2017 Dec; 31(1):48-52. PubMed ID: 28985328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in Albuminuria and Subsequent Risk of Incident Kidney Disease.
    Sumida K; Molnar MZ; Potukuchi PK; George K; Thomas F; Lu JL; Yamagata K; Kalantar-Zadeh K; Kovesdy CP
    Clin J Am Soc Nephrol; 2017 Dec; 12(12):1941-1949. PubMed ID: 28893924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials.
    Basu S; Sussman JB; Rigdon J; Steimle L; Denton BT; Hayward RA
    PLoS Med; 2017 Oct; 14(10):e1002410. PubMed ID: 29040268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Postoperative Acute Kidney Injury Is Associated With Progression of Chronic Kidney Disease Independent of Severity.
    Privratsky JR; Krishnamoorthy V; Raghunathan K; Ohnuma T; Rasouli MR; Long TE; Sigurdsson MI
    Anesth Analg; 2022 Jan; 134(1):49-58. PubMed ID: 34908546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute kidney injury during cisplatin therapy and associations with kidney outcomes 2 to 6 months post-cisplatin in children: a multi-centre, prospective observational study.
    McMahon KR; Lebel A; Rassekh SR; Schultz KR; Blydt-Hansen TD; Cuvelier GDE; Mammen C; Pinsk M; Carleton BC; Tsuyuki RT; Ross CJD; Huynh L; Yordanova M; Crépeau-Hubert F; Wang S; Palijan A; Lee J; Boyko D; Zappitelli M;
    Pediatr Nephrol; 2023 May; 38(5):1667-1685. PubMed ID: 36260162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Meta-analysis of the Association of Estimated GFR, Albuminuria, Diabetes Mellitus, and Hypertension With Acute Kidney Injury.
    James MT; Grams ME; Woodward M; Elley CR; Green JA; Wheeler DC; de Jong P; Gansevoort RT; Levey AS; Warnock DG; Sarnak MJ;
    Am J Kidney Dis; 2015 Oct; 66(4):602-12. PubMed ID: 25975964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased risk for kidney sequelae surrogates in survivors of Wilms tumor.
    Arslan E; Saygili S; Celkan TT; Kurugoglu S; Elicevik M; Camcioglu AE; Konukoglu D; Apak H; Caliskan S; Sever L; Canpolat N
    Pediatr Nephrol; 2022 Oct; 37(10):2415-2426. PubMed ID: 35118543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of the Urine-to-Plasma Urea Ratio With CKD Progression.
    Liu J; Bankir L; Verma A; Waikar SS; Palsson R
    Am J Kidney Dis; 2023 Apr; 81(4):394-405. PubMed ID: 36356680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic kidney disease ten years after pediatric allogeneic hematopoietic stem cell transplantation.
    Lugthart G; Jordans CCE; de Pagter APJ; Bresters D; Jol-van der Zijde CM; Bense JE; van Rooij-Kouwenhoven RWG; Sukhai RN; Louwerens M; Dorresteijn EM; Lankester AC
    Kidney Int; 2021 Oct; 100(4):906-914. PubMed ID: 34102218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimated GFR Variability and Risk of Cardiovascular Events and Mortality in SPRINT (Systolic Blood Pressure Intervention Trial).
    Malhotra R; Katz R; Jotwani V; Agarwal A; Cohen DL; Cushman WC; Ishani A; Killeen AA; Kitzman DW; Oparil S; Papademetriou V; Parikh CR; Raphael KL; Rocco MV; Tamariz LJ; Whelton PK; Wright JT; Shlipak MG; Ix JH
    Am J Kidney Dis; 2021 Jul; 78(1):48-56. PubMed ID: 33333147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modification of the effects of intensive systolic blood pressure control on kidney outcomes by baseline body mass index.
    Agarwal A; Wei G; Boucher R; Ahmed F; Beddhu S
    Nephrology (Carlton); 2021 Apr; 26(4):303-311. PubMed ID: 33538091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-term Blood Pressure Variability and Incident CKD in Patients With Hypertension: Findings From the Cardiovascular and Metabolic Disease Etiology Research Center-High Risk (CMERC-HI) Study.
    Jhee JH; Oh D; Seo J; Lee CJ; Chung MY; Park JT; Han SH; Kang SW; Park S; Yoo TH
    Am J Kidney Dis; 2023 Apr; 81(4):384-393.e1. PubMed ID: 36241008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kidney Damage Biomarkers and Incident Chronic Kidney Disease During Blood Pressure Reduction: A Case-Control Study.
    Zhang WR; Craven TE; Malhotra R; Cheung AK; Chonchol M; Drawz P; Sarnak MJ; Parikh CR; Shlipak MG; Ix JH;
    Ann Intern Med; 2018 Nov; 169(9):610-618. PubMed ID: 30357395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estimated glomerular filtration rate and the risk-benefit profile of intensive blood pressure control amongst nondiabetic patients: a post hoc analysis of a randomized clinical trial.
    Obi Y; Kalantar-Zadeh K; Shintani A; Kovesdy CP; Hamano T
    J Intern Med; 2018 Mar; 283(3):314-327. PubMed ID: 29044764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of Serum Uromodulin with Death, Cardiovascular Events, and Kidney Failure in CKD.
    Steubl D; Schneider MP; Meiselbach H; Nadal J; Schmid MC; Saritas T; Krane V; Sommerer C; Baid-Agrawal S; Voelkl J; Kotsis F; Köttgen A; Eckardt KU; Scherberich JE;
    Clin J Am Soc Nephrol; 2020 May; 15(5):616-624. PubMed ID: 32291270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.